TransMedics Group, Inc. (TMDX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

TransMedics Group, Inc. (TMDX) Healthcare & Pipeline Overview

TransMedics Group, Inc. pioneers organ transplant technology with its Organ Care System (OCS), offering a unique approach to organ preservation. With a focus on improving outcomes in lung, heart, and liver transplants, TransMedics operates in the growing medical device sector, differentiating itself through its proprietary perfusion and monitoring technology.

What Is the Investment Thesis for TMDX?

With a market capitalization of $2.94B and a P/E ratio of 19.24, the company demonstrates strong financial performance, supported by a gross margin of 59.1% and a profit margin of 27.0%. Key growth catalysts include the expansion of OCS technology into new markets and the potential for increased adoption among transplant centers. The ongoing need to address organ shortages and improve transplant success rates positions TransMedics for sustained growth. Potential risks include competition from alternative preservation methods and regulatory hurdles associated with medical device approvals.

Based on FMP financials and quantitative analysis

TMDX Key Highlights

Market Cap of $2.94B reflects investor confidence in TransMedics' growth potential.

• P/E ratio of 19.24 indicates a potentially reasonable valuation relative to earnings.
• Profit Margin of 27.0% demonstrates strong operational efficiency and profitability.
• Gross Margin of 59.1% highlights the value of TransMedics' proprietary technology and pricing power.
• Beta of 2.08 suggests higher volatility compared to the overall market.

Who Are TMDX's Competitors?

TMDX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are TMDX's Key Strengths?

Innovative Organ Care System (OCS) technology.

• Strong clinical evidence supporting OCS benefits.
• Established market presence in organ preservation.
• Experienced management team.

What Are TMDX's Weaknesses?

High cost of OCS technology.

• Limited market penetration compared to traditional methods.
• Reliance on a single product platform.
• Potential for competition from alternative preservation methods.

What Could Drive TMDX Stock Higher?

Publication of clinical trial results demonstrating the benefits of OCS in specific organ transplants.

• Expansion of OCS technology into new transplant centers and geographic regions.
• Development and launch of new OCS applications for additional organs.
• Regulatory approvals for new OCS indications and technologies.

What Are the Key Risks for TMDX?

Regulatory delays in obtaining approvals for new OCS applications.

• Reimbursement challenges from healthcare providers for OCS procedures.
• Competition from established medical device companies and alternative preservation methods.
• Product liability claims related to OCS technology.
• Dependence on key suppliers for critical components of the OCS system.

What Are the Growth Opportunities for TMDX?

• Expansion into New Geographic Markets: TransMedics has the opportunity to expand its OCS technology into new geographic markets, particularly in Europe and Asia. These regions have a growing need for organ transplants and represent a significant market opportunity. Successful expansion would require regulatory approvals and strategic partnerships with transplant centers in these regions. This expansion could contribute significantly to revenue growth within the next 3-5 years.
• Increased Adoption Among Transplant Centers: TransMedics can drive growth by increasing the adoption of its OCS technology among transplant centers in the United States and internationally. This involves demonstrating the clinical and economic benefits of OCS compared to traditional cold storage methods. Increased adoption would lead to higher sales volumes and recurring revenue from OCS consumables and services. This growth opportunity is ongoing and dependent on continued positive clinical outcomes and cost-effectiveness data.
• Development of New OCS Applications: TransMedics can expand its product portfolio by developing new OCS applications for additional organs, such as the kidney and pancreas. This would broaden the company's addressable market and provide new revenue streams. The development of new OCS applications requires significant research and development investment and regulatory approvals. This expansion could materialize within the next 5-7 years.
• Strategic Partnerships and Acquisitions: TransMedics can pursue strategic partnerships and acquisitions to expand its technology portfolio and market reach. This could involve partnering with or acquiring companies with complementary technologies or expertise in organ preservation and transplantation. Strategic partnerships and acquisitions can accelerate growth and provide access to new markets and technologies. The timeline for this growth opportunity is variable and dependent on market conditions and strategic opportunities.
• Focus on Improving Transplant Outcomes: TransMedics can drive growth by focusing on improving transplant outcomes through its OCS technology. This involves conducting clinical studies to demonstrate the benefits of OCS in terms of reduced complications, improved graft survival, and enhanced patient quality of life. Improved transplant outcomes would lead to increased adoption of OCS and strengthen TransMedics' competitive position. This is an ongoing growth opportunity that requires continuous innovation and clinical research.

What Are TMDX's Competitive Advantages?

• Proprietary Organ Care System (OCS) technology.
• Strong intellectual property protection.
• Established relationships with transplant centers and OPOs.
• Clinical evidence supporting the benefits of OCS.
• First-mover advantage in the organ preservation market.

What Does TMDX Do?

TransMedics Group, Inc., founded in 1998 and headquartered in Andover, Massachusetts, is a commercial-stage medical technology company dedicated to revolutionizing organ transplant therapy. The company's core innovation is the Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system designed to maintain donor organs in a near-physiologic state outside the body. This technology aims to improve organ viability and utilization rates, addressing the critical shortage of organs available for transplantation. The OCS technology replicates the conditions within the human body, providing oxygenated blood and nutrients to the organ, while also removing waste products. TransMedics' OCS platform includes specific systems tailored for different organs: OCS LUNG, OCS Heart, and OCS Liver. OCS LUNG is designed for the preservation of standard criteria donor lungs for double-lung transplantation. OCS Heart provides extracorporeal perfusion and preservation of donor hearts. OCS Liver is used for the preservation of donor livers. The company's geographic focus includes the United States and international markets. TransMedics' competitive positioning is centered on its proprietary technology and its potential to improve organ transplant outcomes, setting it apart from traditional cold storage methods.

What Products and Services Does TMDX Offer?

• Develop and commercialize the Organ Care System (OCS) for organ preservation.
• Offer OCS LUNG for preserving standard criteria donor lungs.
• Provide OCS Heart for extracorporeal perfusion and preservation of donor hearts.
• Offer OCS Liver for the preservation of donor livers.
• Transform organ transplant therapy for end-stage organ failure patients.
• Replicate near-physiologic conditions for donor organs outside the human body.
• Provide a portable organ perfusion, optimization, and monitoring system.

How Does TMDX Make Money?

• Sales of Organ Care System (OCS) devices to transplant centers.
• Recurring revenue from OCS consumables and services.
• Revenue from training and support services for OCS users.
• Potential for future revenue from new OCS applications and technologies.

What Industry Does TMDX Operate In?

TransMedics Group, Inc. operates within the medical device industry, specifically targeting the organ transplant market. The industry is characterized by increasing demand for organ transplants and a growing focus on improving organ preservation techniques. The company's OCS technology addresses the critical need to extend the viability of donor organs, potentially increasing the number of successful transplants. Competition includes traditional cold storage methods and emerging technologies aimed at organ preservation and perfusion. The global organ transplant market is projected to continue growing, driven by aging populations and advancements in transplant medicine.

Who Are TMDX's Key Customers?

• Organ transplant centers and hospitals.
• Organ procurement organizations (OPOs).
• Transplant surgeons and medical professionals.
• Patients with end-stage organ failure.

Over the past six months, TransMedics Group, Inc. insiders filed 19 SEC Form 4 transactions — 3 sales and 16 purchases. On net that is roughly 267K shares acquired (about $12.0M) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: TransMedics Group, Inc.

Revenue for TransMedics Group, Inc. came in at $189.9M during Q2 FY2026, a 9.2% improvement versus the preceding quarter. The company recorded net income of $14.7M, with diluted EPS of $0.36. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, TMDX averaged $0.93 in diluted EPS.

TMDX Valuation & Market Position

With a $2.94B market cap, TransMedics Group, Inc. sits in the mid-cap segment of the market. Analyst price targets span from $65.00 to $122.00, with a consensus of $96.86. At the current price of $85.04, that implies approximately 14% upside potential. Relative to its peer group, TMDX's quantitative score of 76/100 is above the peer average of 60/100.

Return on equity for TransMedics Group, Inc. stands at 33.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 10.4%, showing how much profit it generates from its asset base. TMDX trades at a trailing price-to-earnings ratio of 19.24, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 2.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.62 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.1%, the inverse of the P/E and a quick read on earnings relative to price.

TransMedics Group, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.77 places it in the grey zone, a middle ground that warrants monitoring.

TransMedics Group, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 26.9% above estimates on average.

Company Profile

TransMedics Group, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Andover, US. The company is led by CEO Waleed H. Hassanein. TMDX has traded publicly since 2019.

TMDX Financials

TMDX Latest News

TMDX Analyst Consensus

TMDX MoonshotScore

TransMedics Group, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources